S&P 500   4,575.17 (+0.01%)
DOW   35,644.56 (-0.31%)
QQQ   382.24 (+0.82%)
AAPL   149.38 (+0.04%)
MSFT   325.15 (+4.85%)
FB   315.72 (-0.03%)
GOOGL   2,964.87 (+6.41%)
TSLA   1,044.23 (+2.53%)
AMZN   3,408.00 (+0.95%)
NVDA   247.86 (+0.28%)
BABA   169.28 (-0.42%)
NIO   39.64 (-2.05%)
CGC   12.99 (-1.37%)
GE   103.78 (-3.41%)
AMD   123.88 (+0.77%)
MU   68.22 (-1.04%)
T   25.09 (-1.10%)
F   15.75 (-1.19%)
ACB   6.92 (-1.56%)
DIS   170.30 (-1.01%)
PFE   42.84 (-1.65%)
BA   207.17 (-1.26%)
AMC   35.08 (-2.69%)
S&P 500   4,575.17 (+0.01%)
DOW   35,644.56 (-0.31%)
QQQ   382.24 (+0.82%)
AAPL   149.38 (+0.04%)
MSFT   325.15 (+4.85%)
FB   315.72 (-0.03%)
GOOGL   2,964.87 (+6.41%)
TSLA   1,044.23 (+2.53%)
AMZN   3,408.00 (+0.95%)
NVDA   247.86 (+0.28%)
BABA   169.28 (-0.42%)
NIO   39.64 (-2.05%)
CGC   12.99 (-1.37%)
GE   103.78 (-3.41%)
AMD   123.88 (+0.77%)
MU   68.22 (-1.04%)
T   25.09 (-1.10%)
F   15.75 (-1.19%)
ACB   6.92 (-1.56%)
DIS   170.30 (-1.01%)
PFE   42.84 (-1.65%)
BA   207.17 (-1.26%)
AMC   35.08 (-2.69%)
S&P 500   4,575.17 (+0.01%)
DOW   35,644.56 (-0.31%)
QQQ   382.24 (+0.82%)
AAPL   149.38 (+0.04%)
MSFT   325.15 (+4.85%)
FB   315.72 (-0.03%)
GOOGL   2,964.87 (+6.41%)
TSLA   1,044.23 (+2.53%)
AMZN   3,408.00 (+0.95%)
NVDA   247.86 (+0.28%)
BABA   169.28 (-0.42%)
NIO   39.64 (-2.05%)
CGC   12.99 (-1.37%)
GE   103.78 (-3.41%)
AMD   123.88 (+0.77%)
MU   68.22 (-1.04%)
T   25.09 (-1.10%)
F   15.75 (-1.19%)
ACB   6.92 (-1.56%)
DIS   170.30 (-1.01%)
PFE   42.84 (-1.65%)
BA   207.17 (-1.26%)
AMC   35.08 (-2.69%)
S&P 500   4,575.17 (+0.01%)
DOW   35,644.56 (-0.31%)
QQQ   382.24 (+0.82%)
AAPL   149.38 (+0.04%)
MSFT   325.15 (+4.85%)
FB   315.72 (-0.03%)
GOOGL   2,964.87 (+6.41%)
TSLA   1,044.23 (+2.53%)
AMZN   3,408.00 (+0.95%)
NVDA   247.86 (+0.28%)
BABA   169.28 (-0.42%)
NIO   39.64 (-2.05%)
CGC   12.99 (-1.37%)
GE   103.78 (-3.41%)
AMD   123.88 (+0.77%)
MU   68.22 (-1.04%)
T   25.09 (-1.10%)
F   15.75 (-1.19%)
ACB   6.92 (-1.56%)
DIS   170.30 (-1.01%)
PFE   42.84 (-1.65%)
BA   207.17 (-1.26%)
AMC   35.08 (-2.69%)
OTCMKTS:OXBDF

Oxford Biomedica Stock Forecast, Price & News

$21.59
0.00 (0.00 %)
(As of 10/26/2021 12:00 AM ET)
Add
Compare
Today's Range
$21.59
$21.59
50-Day Range
$18.70
$22.85
52-Week Range
$10.25
$22.86
VolumeN/A
Average Volume2,181 shs
Market Capitalization$1.66 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.16
30 days | 90 days | 365 days | Advanced Chart
Receive OXBDF News and Ratings via Email

Sign-up to receive the latest news and ratings for Oxford Biomedica and its competitors with MarketBeat's FREE daily newsletter.


Oxford Biomedica logo

About Oxford Biomedica

Oxford Biomedica plc, a biopharmaceutical company, engages in the research, development, and bioprocessing of lentiviral vector and cell therapy products for the treatment of various diseases in Europe and internationally. The company operates in two segments, Platform and Product. Its LentiVector platform technology integrates genes into non-dividing cells, including neurons in the brain and retinal cells in the eye, as well as accommodates multiple therapeutic genes. The company's products under development stage include OXB-302 that targets haematological tumours with a CAR-T 5T4; OXB-203, which is in pre-clinical stage for the treatment of wet age-related macular degeneration; OXB-204, a lentiviral-based therapy for the ocular disease Leber's congenital amaurosis variant 10; OXB-103 (ALS) for central nervous system; and OXB-401 for liver indication. Its partnered products in development stage comprise AXO-Lenti-PD that is in a Phase I/II trial preparation for the treatment of Parkinson's disease; SAR 422459, which is in a Phase II trial for the treatment of Stargardt disease; and SAR 421869 that is in Phase I/II trial for the treatment of Usher syndrome 1B. Oxford Biomedica plc has partnerships with Novartis, Bristol Myers Squibb, Axovant Gene Therapies, Orchard Therapeutics, Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium, Imperial Innovations, Santen Pharmaceutical Co Ltd, and Vaccines Manufacturing and Innovation Centre. The company also has a research collaboration agreement with Papyrus Therapeutics, Inc. to assess the impact and therapeutic benefit of PYTX-002, a gene replacement therapy to confer cellular pharmacy properties on a CAR-T cell therapy. It has a discovery collaboration with PhoreMost Limited to develop CAR-T cell therapies. Oxford Biomedica plc was founded in 1995 and is headquartered in Oxford, the United Kingdom.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Private households
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:OXBDF
Previous Symbol
NASDAQ:OXBDF
CIK
N/A
Phone
N/A
Employees
673
Year Founded
N/A

Sales & Book Value

Annual Sales
$112.66 million
Cash Flow
$0.06 per share
Book Value
$1.88 per share

Profitability

Debt

Price-To-Earnings

Miscellaneous

Market Cap
$1.66 billion
Next Earnings Date
N/A
Optionable
Not Optionable

MarketRank

Overall MarketRank

1.00 out of 5 stars

Analyst Opinion: 0.0Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -












Oxford Biomedica (OTCMKTS:OXBDF) Frequently Asked Questions

Is Oxford Biomedica a buy right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Oxford Biomedica in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Oxford Biomedica stock.
View analyst ratings for Oxford Biomedica
or view top-rated stocks.

What stocks does MarketBeat like better than Oxford Biomedica?

Wall Street analysts have given Oxford Biomedica a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Oxford Biomedica wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Oxford Biomedica?

Oxford Biomedica saw a increase in short interest in September. As of September 30th, there was short interest totaling 800 shares, an increase of 700.0% from the September 15th total of 100 shares. Based on an average daily volume of 1,700 shares, the short-interest ratio is currently 0.5 days.
View Oxford Biomedica's Short Interest
.

How has Oxford Biomedica's stock been impacted by Coronavirus (COVID-19)?

Oxford Biomedica's stock was trading at $7.7250 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, OXBDF stock has increased by 179.4% and is now trading at $21.5850.
View which stocks have been most impacted by COVID-19
.

Who are Oxford Biomedica's key executives?

Oxford Biomedica's management team includes the following people:
  • Mr. John Dawson, CEO & Exec. Director (Age 61, Pay $1.36M)
  • Mr. Stuart Paynter, CFO, Company Sec. & Director (Age 48, Pay $772.99k)
  • Mr. Nick Page, Chief Operations Officer
  • Dr. James Miskin Ph.D., Chief Technical Officer
  • Dr. Kyriacos Mitrophanous Ph.D., Chief Scientific Officer
  • Ms. Catherine Isted, Head of Corp. Devel. & IR
  • Ms. Natalie Louise Walter, Gen. Counsel
  • Ms. Sarah Macleod, Head of Communications
  • Ms. Helen Stephenson-Ellis, Chief People Officer
  • Dr. Richard Harrop D.Phil. B.Sc., Head of Clinical Analysis

What is Oxford Biomedica's stock symbol?

Oxford Biomedica trades on the OTCMKTS under the ticker symbol "OXBDF."

How do I buy shares of Oxford Biomedica?

Shares of OXBDF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Oxford Biomedica's stock price today?

One share of OXBDF stock can currently be purchased for approximately $21.59.

How much money does Oxford Biomedica make?

Oxford Biomedica has a market capitalization of $1.66 billion and generates $112.66 million in revenue each year. The company earns $-8.02 million in net income (profit) each year or ($0.10) on an earnings per share basis.

How many employees does Oxford Biomedica have?

Oxford Biomedica employs 673 workers across the globe.

What is Oxford Biomedica's official website?

The official website for Oxford Biomedica is www.oxfordbiomedica.co.uk.

Where are Oxford Biomedica's headquarters?

Oxford Biomedica is headquartered at Windrush Court Transport Way, Oxford X0, OX4 6LT.


This page was last updated on 10/27/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.